(MedPage Today) -- Kidney transplant patients who received sirolimus (Rapamune) for immunosuppression were less likely to develop skin cancer than if they were given the older calcineurin inhibitors, a multicenter trial found.
via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment